| Product vision |
|
| MoA |
- ZY19489 new class of inhibitors, no resistance detected in vitro, mechanism of action unknown
- Ferroquine (FQ), a 4-aminoquinoline: inhibition of haem detoxification
|
| Key features |
- ZY19489: No stable resistance detected in in vitro or clinical studies
- FQ: long duration of plasma exposure, fully active against amodiaquine and piperaquine resistant strains
|
| Challenges |
|
| Status |
- ZY19489 phase I Multiple Ascending Dose completed in 2022
- FQ: Two phase II studies in combination with OZ439 were completed in 2020; Ferroquine discovered by CNRS Lille and transferred to Sanofi; rights transferred from Sanofi to MMV
|
| Next milestone |
- Completion of combination toxicology study
- Initiate phase IIb combination study
|
| Previously |
- ZY19489 discovery partnership between MMV and AstraZeneca, Bangalore
- ZY19489 name AZ13721412; full reference name is MMV674253
|
| MMV Project Director |
|
